Elimination of Staphylococcus aureus nasal carriage in intensive care patients lowers infection rates

Eur J Clin Microbiol Infect Dis. 2020 Feb;39(2):333-338. doi: 10.1007/s10096-019-03729-2. Epub 2019 Nov 12.

Abstract

This study surveys the clinical relevance of the nasal Staphylococcus aureus colonization status on intensive care unit (ICU)-acquired S. aureus infections and compares molecular characteristics of isolates from the nose and infectious sites. The 390 patients included comprised 278 non-carriers and 112 carriers. Among the carriers, 56 were decolonized with mupirocin. Decolonization was verified through a second (negative) culture. Spa typing and virulence gene profiling were performed for all isolates. Twenty six S. aureus infections were detected in the carriage group and 20 in the non-carriage group. Eighteen of these 26 (69.2%) infections were among carriers, and 8 of these 26 (30.8%) infections occurred among decolonized carriers (p = 0.02). Overall, 31/112 (27.7%) of the colonized patients and 25/46 (60.1%) of infection were due to methicillin-resistant S. aureus (MRSA). The highest frequency virulence genes were sea and hlg (both 100%) in nasal isolates and sea, hlg, fnb, and clf (100%) for infectious isolates. t030 was the most abundant spa type overall. S. aureus carriers were more likely to develop S. aureus infection compared with decolonized and non-carrying patients. The sources of ICU S. aureus infection appear to be exogenous mostly, and a predominant clone (spa type 030) plays an important role. We confirm that nasal mupirocin treatment prevents ICU infections even when there is an increased prevalence of nosocomial MRSA.

Keywords: Intensive care unit; Nasal carriage; Nosocomial infections; Staphylococcus aureus.

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Bacterial Typing Techniques
  • Carrier State / microbiology*
  • Carrier State / prevention & control
  • Humans
  • Intensive Care Units
  • Iran
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Methicillin-Resistant Staphylococcus aureus / genetics
  • Mupirocin / administration & dosage*
  • Nasal Mucosa / drug effects
  • Nasal Mucosa / microbiology*
  • Prevalence
  • Staphylococcal Infections / microbiology
  • Staphylococcal Infections / prevention & control*
  • Staphylococcus aureus / classification
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / isolation & purification
  • Virulence Factors / genetics

Substances

  • Anti-Bacterial Agents
  • Virulence Factors
  • Mupirocin